Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates

Transfusion

Volumn 54, Issue 5, 2014, Pages 1406-1417

  Klamroth, Robert ^a   Gröner, Albrecht ^b   Simon, Toby L ^c  

^a VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

^b CSL Behring   (Germany)

^c Plasma Research and Development CSL Plasma CSL Behring   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR CONCENTRATE; DETERGENT; NUCLEIC ACID; PLASMA PROTEIN; TRITON X 100;

BLEEDING DISORDER; BLOOD BANK; BLOOD DONOR; BLOOD FILTRATION; BLOOD TRANSFUSION; BLOODBORNE BACTERIUM; CLEANING; CRYOPRECIPITATION; DONOR SELECTION; FRACTIONATION; FREEZE DRYING; HAND WASHING; HEAT TREATMENT; HEMATOLOGICAL PARAMETERS; HEMOPHILIA; HEPATITIS VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOAFFINITY CHROMATOGRAPHY; INDUSTRY; INFECTION PREVENTION; INFECTION RISK; LIFE THREAT; LIPID MEMBRANE; MASS SCREENING; PASTEURIZATION; PHYSIOLOGICAL PROCESS; PLASMA; PLASMAPHERESIS; PRION; PRION DISEASE; PRODUCT SAFETY; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SEROLOGY; VALIDATION STUDY; VAPOR PRESSURE; VIRAL CONTAMINATION; VIRUS; VIRUS EXAMINATION; VIRUS FILTRATION; VIRUS INACTIVATION; VIRUS PARTICLE; VIRUS PATHOGENESIS; VIRUS PURIFICATION; VIRUS REMOVAL; VIRUS TRANSMISSION; VON WILLEBRAND DISEASE;

BLOOD COAGULATION FACTORS; BLOOD SAFETY; BLOOD-BORNE PATHOGENS; FILTRATION; FREEZE DRYING; HOT TEMPERATURE; HUMANS; PASTEURIZATION; PLASMA; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR;

EID: 84900508026     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12423     Document Type: Review

References (103)

1. Kcentra™ (Prothombin Complex Concentrate [Human]). Marburg, Germany: CSL Behring GmbH; 2013.
2. Tabor E,. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 1999; 39: 1160-1168.
3. Mannucci PM, Gdovin S, Gringeri A, et al. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group. Ann Intern Med 1994; 120: 1-7. (Pubitemid 24011493)
4. Mannucci PM,. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates. Vox Sang 1993; 64: 197-203. (Pubitemid 23146497)
5. Azzi A, Ciappi S, Zakvrzewska K, et al. Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates. Am J Hematol 1992; 39: 228-230.
6. Gröner A,. Pathogen safety of plasma-derived products-Haemate-P/ Humate-P. Haemophilia 2008; 14 (s5): 54-71.
7. European Medicines Agency. CHMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products. London, UK: EMA; 2010.
8. US Food and Drug Administration. Guidance for industry: revised preventive measures to reduce the possible risk of transmission of Creutzfeldt-Jakob disease (CJD) and variant Creutzfeldt-Jakob disease (vCJD) by blood and blood products. 2002. [cited 2013 Jan 25]. Available from: http://www.fda.gov/cber/guidelines.html
9. World Health Organization. WHO guidelines on transmissible spongiform encephalopathies in relation to biological and pharmaceutical products. Geneva, Switzerland: WHO; 2003.
10. European Medicines Agency. Guideline on plasma-derived medicinal products. London, UK: EMA; 2011.
11. Farrugia A, Penrod J, Bult JM,. Payment, compensation and replacement-the ethics and motivation of blood and plasma donation. Vox Sang 2010; 99: 202-211.
12. Simon TL,. Monetary compensation for plasma donors: A record of safety. Transfusion 1998; 38: 883-886. (Pubitemid 28421650)
13. World Health Organization. Annex 4. Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. WHO Technical Report, Series No. 924. Geneva, Switzerland; 2004: 150-224.
14. US Food and Drug Administration. Guide to inspections of viral clearance process for plasma derivatives. 2009. [cited 2013 Jan 25]. Available from: http://www.fda.gov/ICECI/Inspections/InspectionGuides/ucm074866.htm
15. Josephson CD, Abshire TC,. Clinical uses of plasma and plasma fractions: plasma-derived products for hemophilias A and B, and for von Willebrand disease. Best Pract Res Clin Haematol 2006; 19: 35-49. (Pubitemid 43118862)
16. Mazurier C,. Composition, quality control, and labeling of plasma-derived products for the treatment of von Willebrand disease. Semin Thromb Hemost 2006; 32: 529-536. (Pubitemid 44157392)
17. ® (Antihemophilic Factor/von Willebrand Factor Complex [Human]). Los Angeles, CA: Grifols Biologicals, Inc.; 2007.
18. ® SD (Coagulation Factor XI [Human]). Los Angeles, CA: Grifols Biologicals, Inc.; 2011.
19. Bebulin (Factor IX Complex). Westlake Village, CA: Baxter Healthcare Corporation; 2011.
20. ® (Coagulation Factor VIII/von Willebrand Factor Complex [Human]). Broadmeadows, Australia: CSL Limited; 2010.
21. Hemofil M Antihemophilic Factor (Human). Glendale, CA: Baxter Healthcare Corporation; 2002.
22. ® -DVI Antihemophilic Factor (Human). Research Triangle Park, NC: Talecris Biotherapeutics, Inc.; 2006.
23. ® (Antihemophilic Factor [Human]). Kankakee, IL: CSL Behring; 2010.
24. ® (Coagulation Factor IX [Human]). Kankakee, IL: CSL Behring; 2011.
25. ® SD (Factor IX Complex). Los Angeles, CA: Grifols Biologicals Inc.; 2011.
26. ® (von Willebrand Factor/Coagulation Factor VIII Complex [Human]). Hoboken, NJ: Octapharma USA Inc.; 2009.
27. ® (Factor XIII Concentrate [Human]). Kankakee, IL: CSL Behring LLC; 2011.
28. Franchini M, Lippi G,. Prothrombin complex concentrates: An update. Blood Transfus 2010; 8: 149-154.
29. Gröner A,. Reply. Pereira A. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion- transmitted infection. Haematologica 2007;92:846-9. Haematologica 2008; 93: e24-26; author reply e27. (Pubitemid 351397730)
30. ® P/N (Human Prothrombin Complex). Ottawa, ON: CSL Behring Canada, Inc.; 2010.
31. ® (Human Prothrombin Complex). Vienna, Austria: Octapharma Pharmazeutika Produktionsges m.b.H.; 2010.
32. ® (Antihemophilic Factor/von Willebrand Factor Complex [Human]). Kankakee, IL: CSL Behring; 2012.
33. Burdick MD, Pifat DY, Petteway SR Jr, et al. Clearance of prions during plasma protein manufacture. Transfus Med Rev 2006; 20: 57-62. (Pubitemid 41811228)
34. Cai K, Gröner A, Dichtelmüller HO, et al. Prion removal capacity of plasma protein manufacturing processes: A data collection from PPTA member companies. Transfusion 2013; 53: 1894-1905.
35. International Conference on Harmonization. Guidance for industry: Q5A viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. Rockville, MD: US FDA; 1997.
36. European Medicines Agency. Note for guidance on quality of biotechnological products: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. London, UK: EMA; 1997.
37. Working Group "Overall Blood Supply Strategy with Regard to Variant Creutzfeldt-Jakob Disease (vCJD)." Report of the Working Group "Overall Blood Supply Strategy with Regard to Variant Creutzfeldt-Jakob Disease (vCJD)": statement on the development and implementation of test systems suitable for the screening of blood donors for vCJD-dated September 17, 2008. Transfus Med Hemother 2009; 36: 79-93.
38. Ironside JW,. Variant Creutzfeldt-Jakob disease: An update. Folia Neuropathol 2012; 50: 50-56.
39. Turner ML, Ludlam CA,. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products. Br J Haematol 2009; 144: 14-23.
40. Edgeworth JA, Farmer M, Sicilia A, et al. Detection of prion infection in variant Creutzfeldt-Jakob disease: A blood-based assay. Lancet 2011; 377 (9764): 487-493.
41. Plasma Protein Therapeutics Association. [cited 2013 Jan 25]. Available from: http://www.pptaglobal.org/
42. Whitaker BI, Schreiber GB, Simon TL,. The residual risk of a window period (WP) unit entering a pool of source plasma. Transfusion 1998; 38 (Suppl): 81S.
43. European Medicines Agency. Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses. London, UK: EMA; 1996.
44. Johnston A, Adcock W,. The use of chromatography to manufacture purer and safer plasma products. Biotechnol Genet Eng Rev 2000; 17: 37-70. (Pubitemid 32157095)
45. Kim IS, Choi YW, Kang Y, et al. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma. J Microbiol Biotechnol 2008; 18: 997-1003.
46. Stadler M, Gruber G, Kannicht C, et al. Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate). Biologicals 2006; 34: 281-288. (Pubitemid 44781195)
47. Johnston A, Macgregor A, Borovec S, et al. Inactivation and clearance of viruses during the manufacture of high purity factor IX. Biologicals 2000; 28: 129-136.
48. Berting A, Modrof J, Unger U, et al. Inactivation of parvovirus B19 during STIM-4 vapor heat treatment of three coagulation factor concentrates. Transfusion 2008; 48: 1220-1226. (Pubitemid 351793485)
49. European Medicines Agency. Guideline on the investigation of manufacturing processes for plasma-derived medicinal products with regard to vCJD risk. London, UK: EMA; 2004.
50. Vey M, Baron H, Weimer T, et al. Purity of spiking agent affects partitioning of prions in plasma protein purification. Biologicals 2002; 30: 187-196. (Pubitemid 36268971)
51. Solheim BG,. Pathogen reduction of blood components. Transfus Apher Sci 2008; 39: 75-82.
52. Dichtelmüller HO, Biesert L, Fabbrizzi F, et al. Robustness of solvent/detergent treatment of plasma derivatives: A data collection from Plasma Protein Therapeutics Association member companies. Transfusion 2009; 49: 1931-1943.
53. Chandra S, Groener A, Feldman F,. Effectiveness of alternative treatments for reducing potential viral contaminants from plasma-derived products. Thromb Res 2002; 105: 391-400. (Pubitemid 34621256)
54. Mannucci PM, Santagostino E, Di Bona E, et al. The outbreak of hepatitis A in Italian patients with hemophilia: facts and fancies. Vox Sang 1994; 67 (Suppl 1): 31-35. (Pubitemid 24175865)
55. Chudy M, Budek I, Keller-Stanislawski B, et al. A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool. J Med Virol 1999; 57: 91-99. (Pubitemid 29022497)
56. Jee YM, Go U, Cheon D, et al. Detection of hepatitis A virus from clotting factors implicated as a source of HAV infection among haemophilia patients in Korea. Epidemiol Infect 2006; 134: 87-93. (Pubitemid 43103533)
57. Saez A, Bosh N, Boadas N, et al. Pharmacokinetics and acute tolerance of a double virus inactivated plasma derived factor VIII concentrate. Haemophilia 1999; 5: 260-265. (Pubitemid 29445751)
58. Smales CM, Pepper DS, James DC,. Protein modification during anti-viral heat-treatment bioprocessing of factor VIII concentrates, factor IX concentrates, and model proteins in the presence of sucrose. Biotechnol Bioeng 2002; 77: 37-48.
59. Unger U, Poelsler G, Modrof J, et al. Virus inactivation during the freeze-drying processes as used for the manufacture of plasma-derived medicinal products. Transfusion 2009; 49: 1924-1930.
60. Roberts PL, Dunkerley C, McAuley A, et al. Effect of manufacturing process parameters on virus inactivation by dry heat treatment at 80 degrees C in factor VIII. Vox Sang 2007; 92: 56-63. (Pubitemid 44950350)
61. Effect of dry-heating of coagulation factor concentrates at 80 degrees C for 72 hours on transmission of non-A, non-B hepatitis. Study Group of the UK Haemophilia Centre Directors on Surveillance of Virus Transmission by Concentrates. Lancet 1988; 2 (8615): 814-816.
62. Arrighi S, Rossi R, Borri MG, et al. "In vitro" and in animal model studies on a double virus-inactivated factor VIII concentrate. Thromb Haemost 1995; 74: 868-873.
63. Blümel J, Schmidt I, Effenberger W, et al. Parvovirus B19 transmission by heat-treated clotting factor concentrates. Transfusion 2002; 42: 1473-1481.
64. Barrett PN, Meyer H, Wachtel I, et al. Inactivation of hepatitis A virus in plasma products by vapor heating. Transfusion 1997; 37: 215-220. (Pubitemid 27091910)
65. Shapiro A, Abe T, Aledort LM, et al. Low risk of viral infection after administration of vapor-heated factor VII concentrate or factor IX complex in first-time recipients of blood components. International Factor Safety Study Group. Transfusion 1995; 35: 204-208.
66. Mannucci PM, Zanetti AR, Colombo M,. Prospective study of hepatitis after factor VIII concentrate exposed to hot vapour. Br J Haematol 1988; 68: 427-430.
67. Burnouf T, Radosevich M,. Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia 2003; 9: 24-37. (Pubitemid 36511630)
68. Lawrence JE,. Affinity chromatography to remove viruses during preparation of plasma derivatives. Dev Biol Stand 1993; 81: 191-197.
69. Roberts PL, Walker CP, Feldman PA,. Removal and inactivation of enveloped and non-enveloped viruses during the purification of a high-purity factor IX by metal chelate affinity chromatography. Vox Sang 1994; 67 (Suppl): 69-71. (Pubitemid 24175875)
70. Mazurier C, Poulle M, Samor B, et al. In vitro study of a triple-secured von Willebrand factor concentrate. Vox Sang 2004; 86: 100-104. (Pubitemid 38436887)
71. Chtourou S, Porte P, Nogre M, et al. A solvent/detergent-treated and 15-nm filtered factor VIII: A new safety standard for plasma-derived coagulation factor concentrates. Vox Sang 2007; 92: 327-337. (Pubitemid 46642980)
72. Gröner A, Nowak T, Popp B, et al. High margin of pathogen safety of a plasma-derived FXIII concentrate. Haemophilia 2012; 18 (Suppl 3): 31.
73. Ironside JW,. Variant Creutzfeldt-Jakob disease. Haemophilia 2010; 16 (Suppl 5): 175-180.
74. Peden A, McCardle L, Head MW, et al. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 2010; 16: 296-304.
75. Ludlam CA, Turner ML,. Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products. Br J Haematol 2006; 132: 13-24. (Pubitemid 43381566)
76. Flechsig E, Hegyi I, Enari M, et al. Transmission of scrapie by steel-surface-bound prions. Mol Med 2001; 7: 679-684. (Pubitemid 33070982)
77. Käsermann F, Kempf C,. Sodium hydroxide renders the prion protein PrPSc sensitive to proteinase K. J Gen Virol 2003; 84 (Pt 11): 3173-3176. (Pubitemid 37336802)
78. Bauman PA, Lawrence LA, Biesert L, et al. Critical factors influencing prion inactivation by sodium hydroxide. Vox Sang 2006; 91: 34-40. (Pubitemid 43822302)
79. Gröner A, Boose JA,. Evaluation of a cleaning procedure for its capacity to remove prions from equipment used in the production of plasma derivatives. Blood 2002; 100 (s): 139b.
80. Okamoto H,. Genetic variability and evolution of hepatitis E virus. Virus Res 2007; 127: 216-228. (Pubitemid 47058196)
81. Juhl D, Baylis SA, Blümel J, et al. Seroprevalence and incidence of hepatitis E virus infection in German blood donors. Transfusion 2014; 54: 49-56.
82. Adlhoch C, Kaiser M, Ellerbrok H, et al. High prevalence of porcine Hokovirus in German wild boar populations. Virol J 2010; 25: 171.
83. Adlhoch C, Kaiser M, Loewa A, et al. Diversity of parvovirus 4-like viruses in humans, chimpanzees, and monkeys in hunter-prey relationships. Emerg Infect Dis 2012; 18: 859-862.
84. Jones MS, Kapoor A, Lukashov VV, et al. New DNA viruses identified in patients with acute viral infection syndrome. J Virol 2005; 79: 8230-8236. (Pubitemid 40853526)
85. Lau SK, Woo PC, Tse H, et al. Identification of novel porcine and bovine parvoviruses closely related to human parvovirus 4. J Gen Virol 2008; 89 (Pt 8): 1840-1848.
86. Sharp CP, LeBreton M, Kantola K, et al. Widespread infection with homologues of human parvoviruses B19, PARV4, and human bocavirus of chimpanzees and gorillas in the wild. J Virol 2010; 84 (19): 10289-10296.
87. Asnis DS, Conetta R, Teixeira AA, et al. The West Nile virus outbreak of 1999 in New York: the Flushing Hospital experience. Clin Infect Dis 2000; 30: 413-418. (Pubitemid 30205281)
88. Cossart YE, Field AM, Cant B, et al. Parvovirus-like particles in human sera. Lancet 1975; 1 (7898): 72-73.
89. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244 (4902): 359-362. (Pubitemid 19117877)
90. Moore PS, Gao SJ, Dominguez G, et al. Primary characterization of a herpesvirus agent associated with Kaposi's sarcomae. J Virol 1996; 70: 549-558. (Pubitemid 126508823)
91. Nishizawa T, Okamoto H, Konishi K, et al. A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. Biochem Biophys Res Commun 1997; 241: 92-97. (Pubitemid 28033544)
92. Sharp CP, Lail A, Donfield S, et al. Virologic and clinical features of primary infection with human parvovirus 4 in subjects with hemophilia: frequent transmission by virally inactivated clotting factor concentrates. Transfusion 2012; 52: 1482-1489.
93. Eis-Hübinger AM, Drexler JF, Reber U, et al. Absence of detection of novel human parvoviruses in German plasma donations. Transfusion 2010; 50: 266-267.
94. Vallerini D, Barozzi P, Quadrelli C, et al. Parvoviruses in blood donors and transplant patients, Italy. Emerg Infect Dis 2008; 14: 185-186.
95. Fryer JF, Kapoor A, Minor PD, et al. Novel parvovirus and related variant in human plasma. Emerg Infect Dis 2006; 12: 151-154. (Pubitemid 43143554)
96. Modrow S, Wenzel JJ, Schimanski S, et al. Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates. Vox Sang 2011; 100: 351-358.
97. Fryer JF, Hubbard AR, Baylis SA,. Human parvovirus PARV4 in clotting factor VIII concentrates. Vox Sang 2007; 93: 341-347. (Pubitemid 350135083)
98. Schneider B, Fryer JF, Oldenburg J, et al. Frequency of contamination of coagulation factor concentrates with novel human parvovirus PARV4. Haemophilia 2008; 14: 978-986.
99. Kreil TR, Berting A, Kistner O, et al. West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data. Transfusion 2003; 43: 1023-1028. (Pubitemid 37022360)
100. Xie YW, Chan PK, Szeto CK, et al. Clearance of dengue virus in the plasma-derived therapeutic proteins. Transfusion 2008; 48: 1342-1347.
101. Leydold SM, Farcet MR, Kindermann J, et al. Chikungunya virus and the safety of plasma products. Transfusion 2012; 52: 2122-2130.
102. ® (Pooled Plasma [Human]). Vienna, Austria: Octapharma Pharmazeutika Produktionsges m.b.H.; 2013.
103. Horowitz B, Prince AM, Horowitz MS, et al. Viral safety of solvent-detergent treated blood products. Dev Biol Stand 1993; 81: 147-161.